The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.
 
Maura L. Gillison
Consulting or Advisory Role - Bayer; Bicara Therapeutics; BioNTech; BioNTech; Bristol-Myers Squibb; Debiopharm Group; EMD Serono; Gilead Sciences; Ipsen; Kura Oncology; Merck; Roche; Shattuck Labs
Research Funding - Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genocea Biosciences (Inst)
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Przemyslaw Twardowski
Honoraria - Astellas Medivation; Bayer; Genentech/Roche; Janssen; Sanofi/Aventis
Consulting or Advisory Role - Janssen; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; Bayer; Genentech/Roche; Janssen; Sanofi
 
Ammar Sukari
Stock and Other Ownership Interests - Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Amgen (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PMV Pharma (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme; Xencor
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
Richard Hernandez
Employment - Genocea Biosciences
Stock and Other Ownership Interests - Genocea Biosciences
Travel, Accommodations, Expenses - Genocea Biosciences
 
Jessica Price
Employment - Genocea Biosciences
Stock and Other Ownership Interests - Genocea Biosciences
 
Kevin J. Mancini
Employment - Genocea Biosciences
Stock and Other Ownership Interests - Genocea Biosciences
 
Mara Shainheit
Employment - Genocea Biosciences
Stock and Other Ownership Interests - Genocea Biosciences; Genocea Biosciences
Research Funding - Genocea Biosciences
 
Vijetha Vemulapalli
No Relationships to Disclose
 
Jessica Flechtner
Employment - Genocea Biosciences
Leadership - Genocea Biosciences
Stock and Other Ownership Interests - Genocea Biosciences
Research Funding - Genocea Biosciences
Patents, Royalties, Other Intellectual Property - Inventor on issued and pending patents at Genocea Biosciences
Travel, Accommodations, Expenses - Genocea Biosciences
 
Thomas A. Davis
Employment - Genocea Biosciences
Leadership - Genocea Biosciences
Stock and Other Ownership Interests - Genocea Biosciences
Travel, Accommodations, Expenses - Genocea Biosciences
 
Roger B. Cohen
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; Cantargia AB; Genocea Biosciences; Heat Biologics; Innate Pharma; Xencor
Research Funding - AstraZeneca (Inst); Celldex (Inst); Genocea Biosciences (Inst); Heat Biologics (Inst); Innate Pharma (Inst); Kyn therapeutics (Inst); Merck (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Genocea Biosciences; Innate Pharma